Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom

Martina Recalde; Elena Roel; Andrea Pistillo; Anthony G. Sena; Albert Prats-Uribe; Waheed-Ul-Rahman Ahmed; Heba Alghoul; Thamir M. Alshammari; Osaid Alser; Carlos Areia; Edward Burn; Paula Casajust; Dalia Dawoud; Scott L. DuVall; Thomas Falconer; Sergio Fernández-Bertolín; Asieh Golozar; Mengchun Gong; Lana Yin Hui Lai; Jennifer C. E. Lane; Kristine E. Lynch; Michael E. Matheny; Paras P. Mehta; Daniel R. Morales; Karthik Natarjan; Fredrik Nyberg; Jose D. Posada; Christian G. Reich; Peter R. Rijnbeek; Lisa M. Schilling; Karishma Shah; Nigam H. Shah; Vignesh Subbian; Lin Zhang; Hong Zhu; Patrick Ryan; Daniel Prieto-Alhambra; Kristin Kostka; Talita Duarte-Salles

doi:10.1038/s41366-021-00893-4

Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom

Martina Recalde
, Elena Roel
, Andrea Pistillo
, Anthony G. Sena
, Albert Prats-Uribe
, Waheed-Ul-Rahman Ahmed
, Heba Alghoul
, Thamir M. Alshammari
, Osaid Alser
, Carlos Areia
, Edward Burn
, Paula Casajust
, Dalia Dawoud
, Scott L. DuVall
, Thomas Falconer
, Sergio Fernández-Bertolín
, Asieh Golozar
, Mengchun Gong
, Lana Yin Hui Lai
, Jennifer C. E. Lane

Kristine E. Lynch, Michael E. Matheny, Paras P. Mehta, Daniel R. Morales, Karthik Natarjan, Fredrik Nyberg, Jose D. Posada, Christian G. Reich, Peter R. Rijnbeek, Lisa M. Schilling, Karishma Shah, Nigam H. Shah, Vignesh Subbian, Lin Zhang, Hong Zhu, Patrick Ryan, Daniel Prieto-Alhambra, Kristin Kostka, Talita Duarte-Salles (Lead / Corresponding author)

Population Health and Genomics

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

125 Downloads (Pure)

Abstract

Background: A detailed characterization of patients with COVID-19 living with obesity has not yet been undertaken. We aimed to describe and compare the demographics, medical conditions, and outcomes of COVID-19 patients living with obesity (PLWO) to those of patients living without obesity.

Methods: We conducted a cohort study based on outpatient/inpatient care and claims data from January to June 2020 from Spain, the UK, and the US. We used six databases standardized to the OMOP common data model. We defined two non-mutually exclusive cohorts of patients diagnosed and/or hospitalized with COVID-19; patients were followed from index date to 30 days or death. We report the frequency of demographics, prior medical conditions, and 30-days outcomes (hospitalization, events, and death) by obesity status.

Results: We included 627 044 (Spain: 122 058, UK: 2336, and US: 502 650) diagnosed and 160 013 (Spain: 18 197, US: 141 816) hospitalized patients with COVID-19. The prevalence of obesity was higher among patients hospitalized (39.9%, 95%CI: 39.8-40.0) than among those diagnosed with COVID-19 (33.1%; 95%CI: 33.0-33.2). In both cohorts, PLWO were more often female. Hospitalized PLWO were younger than patients without obesity. Overall, COVID-19 PLWO were more likely to have prior medical conditions, present with cardiovascular and respiratory events during hospitalization, or require intensive services compared to COVID-19 patients without obesity.

Conclusion: We show that PLWO differ from patients without obesity in a wide range of medical conditions and present with more severe forms of COVID-19, with higher hospitalization rates and intensive services requirements. These findings can help guiding preventive strategies of COVID-19 infection and complications and generating hypotheses for causal inference studies.

Original language	English
Pages (from-to)	2347-2357
Number of pages	11
Journal	International Journal of Obesity
Volume	45
Early online date	15 Jul 2021
DOIs	https://doi.org/10.1038/s41366-021-00893-4
Publication status	Published - Nov 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Epidemiology
Public health

Access to Document

10.1038/s41366-021-00893-4Licence: CC BY

Final Published VersionFinal published version, 2.34 MBLicence: CC BY

Approaches for Creating Clinical Evidence of Treatment Effects in Routine Populations Excluded from Trials (ACCEPT) (Clinical Research Career Development Fellowship)
Morales, D. (Investigator)
1/12/19 → 31/05/23
Project: Research

Cite this

Recalde, M., Roel, E., Pistillo, A., Sena, A. G., Prats-Uribe, A., Ahmed, W.-U.-R., Alghoul, H., Alshammari, T. M., Alser, O., Areia, C., Burn, E., Casajust, P., Dawoud, D., DuVall, S. L., Falconer, T., Fernández-Bertolín, S., Golozar, A., Gong, M., Lai, L. Y. H., ... Duarte-Salles, T. (2021). Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom. International Journal of Obesity, 45, 2347-2357. https://doi.org/10.1038/s41366-021-00893-4

@article{b9bab60eda84472a8c2821104c994186,

title = "Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom",

abstract = "Background: A detailed characterization of patients with COVID-19 living with obesity has not yet been undertaken. We aimed to describe and compare the demographics, medical conditions, and outcomes of COVID-19 patients living with obesity (PLWO) to those of patients living without obesity.Methods: We conducted a cohort study based on outpatient/inpatient care and claims data from January to June 2020 from Spain, the UK, and the US. We used six databases standardized to the OMOP common data model. We defined two non-mutually exclusive cohorts of patients diagnosed and/or hospitalized with COVID-19; patients were followed from index date to 30 days or death. We report the frequency of demographics, prior medical conditions, and 30-days outcomes (hospitalization, events, and death) by obesity status.Results: We included 627 044 (Spain: 122 058, UK: 2336, and US: 502 650) diagnosed and 160 013 (Spain: 18 197, US: 141 816) hospitalized patients with COVID-19. The prevalence of obesity was higher among patients hospitalized (39.9\%, 95\%CI: 39.8-40.0) than among those diagnosed with COVID-19 (33.1\%; 95\%CI: 33.0-33.2). In both cohorts, PLWO were more often female. Hospitalized PLWO were younger than patients without obesity. Overall, COVID-19 PLWO were more likely to have prior medical conditions, present with cardiovascular and respiratory events during hospitalization, or require intensive services compared to COVID-19 patients without obesity.Conclusion: We show that PLWO differ from patients without obesity in a wide range of medical conditions and present with more severe forms of COVID-19, with higher hospitalization rates and intensive services requirements. These findings can help guiding preventive strategies of COVID-19 infection and complications and generating hypotheses for causal inference studies.",

keywords = "Epidemiology, Public health",

author = "Martina Recalde and Elena Roel and Andrea Pistillo and Sena, \{Anthony G.\} and Albert Prats-Uribe and Waheed-Ul-Rahman Ahmed and Heba Alghoul and Alshammari, \{Thamir M.\} and Osaid Alser and Carlos Areia and Edward Burn and Paula Casajust and Dalia Dawoud and DuVall, \{Scott L.\} and Thomas Falconer and Sergio Fern{\'a}ndez-Bertol{\'i}n and Asieh Golozar and Mengchun Gong and Lai, \{Lana Yin Hui\} and Lane, \{Jennifer C. E.\} and Lynch, \{Kristine E.\} and Matheny, \{Michael E.\} and Mehta, \{Paras P.\} and Morales, \{Daniel R.\} and Karthik Natarjan and Fredrik Nyberg and Posada, \{Jose D.\} and Reich, \{Christian G.\} and Rijnbeek, \{Peter R.\} and Schilling, \{Lisa M.\} and Karishma Shah and Shah, \{Nigam H.\} and Vignesh Subbian and Lin Zhang and Hong Zhu and Patrick Ryan and Daniel Prieto-Alhambra and Kristin Kostka and Talita Duarte-Salles",

note = "The European Health Data \& Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation program and EFPIA. This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Center (BRC), US National Institutes of Health, US Department of Veterans Affairs, Janssen Research \& Development, and IQVIA. The University of Oxford received funding related to this work from the Bill \& Melinda Gates Foundation (Investment ID INV-016201 and INV-019257). APU has received funding from the Medical Research Council (MRC) [MR/K501256/1, MR/N013468/1] and Fundaci{\'o}n Alfonso Mart{\'i}n Escudero (FAME) (APU). VINCI [VA HSR RES 13-457] (SLD, MEM, KEL). JCEL has received funding from the Medical Research Council (MR/K501256/1) and Versus Arthritis (21605). MR is funded by Wereld Kanker Onderzoek Fonds (WKOF), as part of the World Cancer Research Fund International grant program [grant number: 2017/1630]. No funders had a direct role in this study. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Clinician Scientist Award program, NIHR, Department of Veterans Affairs or the United States Government, NHS, or the Department of Health, England. ",

year = "2021",

month = nov,

doi = "10.1038/s41366-021-00893-4",

language = "English",

volume = "45",

pages = "2347--2357",

journal = "International Journal of Obesity",

issn = "0307-0565",

publisher = "Springer Nature",

}

Recalde, M, Roel, E, Pistillo, A, Sena, AG, Prats-Uribe, A, Ahmed, W-U-R, Alghoul, H, Alshammari, TM, Alser, O, Areia, C, Burn, E, Casajust, P, Dawoud, D, DuVall, SL, Falconer, T, Fernández-Bertolín, S, Golozar, A, Gong, M, Lai, LYH, Lane, JCE, Lynch, KE, Matheny, ME, Mehta, PP, Morales, DR, Natarjan, K, Nyberg, F, Posada, JD, Reich, CG, Rijnbeek, PR, Schilling, LM, Shah, K, Shah, NH, Subbian, V, Zhang, L, Zhu, H, Ryan, P, Prieto-Alhambra, D, Kostka, K & Duarte-Salles, T 2021, 'Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom', International Journal of Obesity, vol. 45, pp. 2347-2357. https://doi.org/10.1038/s41366-021-00893-4

TY - JOUR

T1 - Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom

AU - Recalde, Martina

AU - Roel, Elena

AU - Pistillo, Andrea

AU - Sena, Anthony G.

AU - Prats-Uribe, Albert

AU - Ahmed, Waheed-Ul-Rahman

AU - Alghoul, Heba

AU - Alshammari, Thamir M.

AU - Alser, Osaid

AU - Areia, Carlos

AU - Burn, Edward

AU - Casajust, Paula

AU - Dawoud, Dalia

AU - DuVall, Scott L.

AU - Falconer, Thomas

AU - Fernández-Bertolín, Sergio

AU - Golozar, Asieh

AU - Gong, Mengchun

AU - Lai, Lana Yin Hui

AU - Lane, Jennifer C. E.

AU - Lynch, Kristine E.

AU - Matheny, Michael E.

AU - Mehta, Paras P.

AU - Morales, Daniel R.

AU - Natarjan, Karthik

AU - Nyberg, Fredrik

AU - Posada, Jose D.

AU - Reich, Christian G.

AU - Rijnbeek, Peter R.

AU - Schilling, Lisa M.

AU - Shah, Karishma

AU - Shah, Nigam H.

AU - Subbian, Vignesh

AU - Zhang, Lin

AU - Zhu, Hong

AU - Ryan, Patrick

AU - Prieto-Alhambra, Daniel

AU - Kostka, Kristin

AU - Duarte-Salles, Talita

N1 - The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Center (BRC), US National Institutes of Health, US Department of Veterans Affairs, Janssen Research & Development, and IQVIA. The University of Oxford received funding related to this work from the Bill & Melinda Gates Foundation (Investment ID INV-016201 and INV-019257). APU has received funding from the Medical Research Council (MRC) [MR/K501256/1, MR/N013468/1] and Fundación Alfonso Martín Escudero (FAME) (APU). VINCI [VA HSR RES 13-457] (SLD, MEM, KEL). JCEL has received funding from the Medical Research Council (MR/K501256/1) and Versus Arthritis (21605). MR is funded by Wereld Kanker Onderzoek Fonds (WKOF), as part of the World Cancer Research Fund International grant program [grant number: 2017/1630]. No funders had a direct role in this study. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Clinician Scientist Award program, NIHR, Department of Veterans Affairs or the United States Government, NHS, or the Department of Health, England.

PY - 2021/11

Y1 - 2021/11

N2 - Background: A detailed characterization of patients with COVID-19 living with obesity has not yet been undertaken. We aimed to describe and compare the demographics, medical conditions, and outcomes of COVID-19 patients living with obesity (PLWO) to those of patients living without obesity.Methods: We conducted a cohort study based on outpatient/inpatient care and claims data from January to June 2020 from Spain, the UK, and the US. We used six databases standardized to the OMOP common data model. We defined two non-mutually exclusive cohorts of patients diagnosed and/or hospitalized with COVID-19; patients were followed from index date to 30 days or death. We report the frequency of demographics, prior medical conditions, and 30-days outcomes (hospitalization, events, and death) by obesity status.Results: We included 627 044 (Spain: 122 058, UK: 2336, and US: 502 650) diagnosed and 160 013 (Spain: 18 197, US: 141 816) hospitalized patients with COVID-19. The prevalence of obesity was higher among patients hospitalized (39.9%, 95%CI: 39.8-40.0) than among those diagnosed with COVID-19 (33.1%; 95%CI: 33.0-33.2). In both cohorts, PLWO were more often female. Hospitalized PLWO were younger than patients without obesity. Overall, COVID-19 PLWO were more likely to have prior medical conditions, present with cardiovascular and respiratory events during hospitalization, or require intensive services compared to COVID-19 patients without obesity.Conclusion: We show that PLWO differ from patients without obesity in a wide range of medical conditions and present with more severe forms of COVID-19, with higher hospitalization rates and intensive services requirements. These findings can help guiding preventive strategies of COVID-19 infection and complications and generating hypotheses for causal inference studies.

AB - Background: A detailed characterization of patients with COVID-19 living with obesity has not yet been undertaken. We aimed to describe and compare the demographics, medical conditions, and outcomes of COVID-19 patients living with obesity (PLWO) to those of patients living without obesity.Methods: We conducted a cohort study based on outpatient/inpatient care and claims data from January to June 2020 from Spain, the UK, and the US. We used six databases standardized to the OMOP common data model. We defined two non-mutually exclusive cohorts of patients diagnosed and/or hospitalized with COVID-19; patients were followed from index date to 30 days or death. We report the frequency of demographics, prior medical conditions, and 30-days outcomes (hospitalization, events, and death) by obesity status.Results: We included 627 044 (Spain: 122 058, UK: 2336, and US: 502 650) diagnosed and 160 013 (Spain: 18 197, US: 141 816) hospitalized patients with COVID-19. The prevalence of obesity was higher among patients hospitalized (39.9%, 95%CI: 39.8-40.0) than among those diagnosed with COVID-19 (33.1%; 95%CI: 33.0-33.2). In both cohorts, PLWO were more often female. Hospitalized PLWO were younger than patients without obesity. Overall, COVID-19 PLWO were more likely to have prior medical conditions, present with cardiovascular and respiratory events during hospitalization, or require intensive services compared to COVID-19 patients without obesity.Conclusion: We show that PLWO differ from patients without obesity in a wide range of medical conditions and present with more severe forms of COVID-19, with higher hospitalization rates and intensive services requirements. These findings can help guiding preventive strategies of COVID-19 infection and complications and generating hypotheses for causal inference studies.

KW - Epidemiology

KW - Public health

U2 - 10.1038/s41366-021-00893-4

DO - 10.1038/s41366-021-00893-4

M3 - Article

C2 - 34267326

SN - 0307-0565

VL - 45

SP - 2347

EP - 2357

JO - International Journal of Obesity

JF - International Journal of Obesity

ER -

Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Projects

Approaches for Creating Clinical Evidence of Treatment Effects in Routine Populations Excluded from Trials (ACCEPT) (Clinical Research Career Development Fellowship)

Cite this